Cesare Riccardo Sirtori

Cesare Riccardo Sirtori's AcademicInfluence.com Rankings

Philosophy

#4613

World Rank

#7198

Historical Rank

Logic

#2034

World Rank

#2930

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Cesare Riccardo Sirtori's Degrees

PhD Biomedical Sciences University of Milan
Doctorate Medicine University of Milan

Why Is Cesare Riccardo Sirtori Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Cesare Riccardo Sirtori's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study (2013) (579)
A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. (1980) (447)
The pharmacology of statins. (2014) (435)
Aescin: pharmacology, pharmacokinetics and therapeutic profile. (2001) (364)
SOYBEAN-PROTEIN DIET IN THE TREATMENT OF TYPE-II HYPERLIPOPROTEINÆMIA (1977) (318)
Cardiovascular Status of Carriers of the Apolipoprotein A-IMilano Mutant: The Limone sul Garda Study (2001) (309)
Carotid Artery Intima-Media Thickness Measured by Ultrasonography in Normal Clinical Practice Correlates Well With Atherosclerosis Risk Factors (2000) (279)
Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. (1996) (276)
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C* (2004) (265)
Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells. (2000) (223)
Disposition of metformin (N,N‐dimethylbiguanide) in man (1978) (219)
Proteins of white lupin seed, a naturally isoflavone-poor legume, reduce cholesterolemia in rats and increase LDL receptor activity in HepG2 cells. (2004) (218)
Controlled evaluation of fat intake in the Mediterranean diet: comparative activities of olive oil and corn oil on plasma lipids and platelets in high-risk patients. (1986) (212)
Recombinant Apolipoprotein A-IMilano Infusion Into Rabbit Carotid Artery Rapidly Removes Lipid From Fatty Streaks (2002) (199)
Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. (1995) (197)
A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. (1980) (183)
Phytoestrogens: End of a tale? (2005) (180)
Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. (1994) (176)
Soybean protein diet increases low density lipoprotein receptor activity in mononuclear cells from hypercholesterolemic patients. (1987) (175)
Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. (1997) (166)
Soy and cholesterol reduction: clinical experience. (1995) (155)
Clinical experience with the soybean protein diet in the treatment of hypercholesterolemia. (1979) (150)
MULTICENTRE STUDY OF SOYBEAN PROTEIN DIET FOR OUTPATIENT HYPERCHOLESTEROLÆMIC PATIENTS (1980) (144)
Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. (1983) (144)
PPAR Agonists and Metabolic Syndrome: An Established Role? (2018) (139)
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. (1997) (139)
Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout. (1993) (139)
Inhibition of lipolysis by nicotinic acid and by acipimox (1980) (138)
Evaluation of Selected Hypolipidemic Agents for the Induction of Peroxisomal Enzymes and Peroxisome Proliferation in the Rat Liver (1983) (133)
Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans (2009) (130)
Effects of yoghurt enriched with plant sterols on serum lipids in patients with moderate hypercholesterolaemia (2001) (123)
An ω-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia (2004) (122)
Increased platelet sensitivity and thromboxane B2 formation in type‐II hyperlipoproteinaemic patients (1984) (121)
Apolipoprotein E ε4 Allele in Alzheimer's Disease and Vascular Dementia (1994) (121)
Effects of dietary proteins on the regulation of liver lipoprotein receptors in rats. (1984) (120)
Reverse cholesterol transport: physiology and pharmacology. (1991) (117)
Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. (1999) (116)
AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. (1985) (115)
Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: Focus on dietary proteins. (2009) (114)
Soy proteins and cardiovascular disease (2001) (114)
In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia. (1993) (114)
Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. (2000) (114)
Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. (1989) (113)
One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. (1998) (113)
Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. (2013) (108)
Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism. Part 1. Chemical composition of very low density lipoproteins in rabbits. (1976) (103)
Low density lipoprotein receptor activity is modulated by soybean globulins in cell culture. (1992) (102)
Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. (1995) (98)
Carotid intima‐media thickness and markers of inflammation, endothelial damage and hemostasis (2008) (96)
Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. (2007) (95)
Olive oil, corn oil, and n-3 fatty acids differently affect lipids, lipoproteins, platelets, and superoxide formation in type II hypercholesterolemia. (1992) (94)
Risks and Benefits of Soy Phytoestrogens in Cardiovascular Diseases, Cancer, Climacteric Symptoms and Osteoporosis (2001) (94)
N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. (1997) (94)
A proteomic investigation of isolated soy proteins with variable effects in experimental and clinical studies. (2003) (93)
Omega-3 fatty acid ethyl esters increase heart rate variability in patients with coronary disease. (2002) (87)
Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. (2008) (87)
Effects of Guar-enriched pasta in the treatment of diabetes and hyperlipidemia. (1984) (86)
Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. (2017) (85)
Apolipoprotein A-I(Milano): current perspectives. (2003) (84)
Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. (1993) (84)
Soybean Protein Diet and Plasma Cholesterol: From Therapy to Molecular Mechanisms (1993) (83)
Hypolipidaemic and anti-atherosclerotic effects of lupin proteins in a rabbit model (2008) (81)
Reduction of serum cholesterol by soy proteins: Clinical experience and potential molecular mechanisms (1998) (81)
Role of isoflavones in the cholesterol reduction by soy proteins in the clinic. (1997) (80)
An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. (2004) (78)
Very low intakes of N-3 fatty acids incorporated into bovine milk reduce plasma triacylglycerol and increase HDL-cholesterol concentrations in healthy subjects. (2000) (78)
Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. (1972) (77)
Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. (2014) (76)
Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals (2011) (74)
Apolipoprotein A-IMilano: current perspectives (2003) (74)
Non-pharmacological control of plasma cholesterol levels. (2008) (71)
Risk identification and possible countermeasures for muscle adverse effects during statin therapy. (2015) (70)
Functional foods for dyslipidaemia and cardiovascular risk prevention (2009) (70)
Apolipoprotein AIMilano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant. (1985) (70)
Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. (1994) (69)
Common Carotid Intima‐Media Thickness Measurement: A Method to Improve Accuracy and Precision (1994) (69)
Soybean Protein Products as Regulators of Liver Low-Density Lipoprotein Receptors. I. Identification of Active β-Conglycinin Subunits (1998) (69)
Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. (1996) (67)
A Unique Protease-sensitive High Density Lipoprotein Particle Containing the Apolipoprotein A-IMilano Dimer Effectively Promotes ATP-binding Cassette A1-mediated Cell Cholesterol Efflux* (2007) (67)
Effects of fibrates on serum lipids and atherosclerosis. (1988) (66)
Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. (2007) (66)
Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. (1984) (65)
L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). (2000) (64)
PCSK9 inhibition and inflammation: A narrative review. (2019) (64)
Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. (2007) (63)
Metformin Improves Peripheral Vascular Flow in Nonhyperlipidemic Patients with Arterial Disease (1984) (63)
Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns. (1985) (63)
A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES. (2019) (62)
Clinical approach to the inflammatory etiology of cardiovascular diseases (2020) (61)
Dietary treatment for familial hypercholesterolemia--differential effects of dietary soy protein according to the apolipoprotein E phenotypes. (1991) (61)
Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk – Results from the PROG-IMT collaboration (2018) (59)
Hypocholesterolaemic effects of soya proteins: results of recent studies are predictable from the anderson meta-analysis data. (2007) (58)
Hypercholesterolaemia treated by soybean protein diet. (1987) (58)
Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population. (1993) (58)
Fecal cholesterol excretion studies in type II hypercholesterolemic patients treated with the soybean protein diet. (1982) (58)
7S globulin from soybean is metabolized in human cell cultures by a specific uptake and degradation system. (1996) (58)
Cardiac, skeletal, and ocular abnormalities in patients with Marfan's syndrome and in their relatives. Comparison with the cardiac abnormalities in patients with kyphoscoliosis. (1984) (57)
Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. (1998) (56)
Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. (2000) (56)
Platelet aggreation malondialdehyde formation in type IIA hypercholesterolemic patients. (1979) (56)
Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. (1989) (55)
N-3 fatty acids and diabetes. (2002) (55)
Clinical response to statins: Mechanism(s) of variable activity and adverse effects (2012) (55)
Reconstituted high-density lipoproteins with a disulfide-linked apolipoprotein A-I dimer: evidence for restricted particle size heterogeneity. (1997) (55)
n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes. (1994) (55)
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study (2006) (55)
Recombinant apolipoproteins for the treatment of vascular diseases. (1999) (53)
Hyperlipoproteinemia in alcoholic subjects (1973) (51)
Statin therapy and related risk of new-onset type 2 diabetes mellitus. (2014) (51)
Soybean Protein Products as Regulators of Liver Low-Density Lipoprotein Receptors. II. α−α‘ Rich Commercial Soy Concentrate and α‘ Deficient Mutant Differently Affect Low-Density Lipoprotein Receptor Activation (1998) (51)
Synthetic High-Density Lipoproteins Exert Cardioprotective Effects in Myocardial Ischemia/Reperfusion Injury (2004) (50)
The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). (2020) (50)
Differential effect of unsaturated oils and butter on blood glucose and insulin response to carbohydrate in normal volunteers. (1992) (50)
Cholesterol-lowering and HDL-raising properties of lecithinated soy proteins in type II hyperlipidemic patients. (1985) (50)
Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy (2017) (50)
Treatment of hypertriglyceridemia with metformin. Effectiveness and analỳsis of results. (1977) (48)
LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. A lesson from cholesterol turnover studies and others. (2006) (48)
High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. (2005) (48)
Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients (1991) (47)
Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. (1995) (47)
Platelet formation of 12-hydroxyeicosatetraenoic acid and thromboxane B2 is increased in type IIA hypercholesterolemic subjects. (1986) (46)
Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk (2011) (46)
Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. (2000) (46)
Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. (1990) (46)
Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis. (1981) (46)
Decreased high density lipoprotein-cholesterol levels in male patients with transient ischemic attacks. (1979) (46)
Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial (2018) (45)
Hypolipidemic effect of dietary pea proteins: Impact on genes regulating hepatic lipid metabolism. (2010) (45)
Unravelling the health effects of fasting: a long road from obesity treatment to healthy life span increase and improved cognition (2020) (45)
Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases (2006) (45)
Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. (2001) (45)
Apolipoprotein AIMilano. Partial lecithin:cholesterol acyltransferase deficiency due to low levels of a functional enzyme. (1990) (44)
Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. (1989) (44)
Double-blind study of the addition of high-protein soya milk v. cows' milk to the diet of patients with severe hypercholesterolaemia and resistance to or intolerance of statins (1999) (43)
Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. (2002) (43)
Apolipoprotein AIMilano. Disulfide-linked dimers increase high density lipoprotein stability and hinder particle interconversion in carrier plasma. (1990) (42)
A Salmon Protein Hydrolysate Exerts Lipid-Independent Anti-Atherosclerotic Activity in ApoE-Deficient Mice (2014) (42)
Increased keratin content detected by proteomic analysis of exhaled breath condensate from healthy persons who smoke. (2004) (42)
Present therapeutic role of cholesteryl ester transfer protein inhibitors (2018) (42)
Novel pyrimidine and 1,3,5-triazine hypolipidemic agents. (1984) (42)
Plasma lipoproteins affect platelet malondialdehyde and thromboxane B2 production. (1985) (41)
Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound. (2000) (41)
Plasma Lipid and Lipoprotein Changes in Hypertensive Patients Treated with Propranolol and Prazosin (1982) (40)
Apolipoprotein E epsilon 4 allele in Alzheimer's disease and vascular dementia. (1994) (40)
Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities. (1993) (40)
Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. (2000) (40)
Increased Carotid Artery Intima-Media Thickness in Subjects With Primary Hypoalphalipoproteinemia (2002) (39)
Appropriateness of statin prescription in the elderly. (2018) (39)
Effects of Timing and Extent of Smoking, Type of Cigarettes, and Concomitant Risk Factors on the Association Between Smoking and Subclinical Atherosclerosis (2009) (39)
Dietary animal proteins and cholesterol metabolism in rabbits (1990) (39)
PPAR-α agonists are still on the rise: an update on clinical and experimental findings (2017) (39)
PCSK9: a view beyond the canonical cholesterol lowering impact. (2021) (38)
Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. (2018) (38)
Reduced HDL2 levels in myocardial infarction patients without risk factors for atherosclerosis. (1987) (38)
Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study (2019) (38)
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia. (2020) (38)
Metaformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits. (1977) (38)
Effects of storage on the distribution of high density lipoprotein subfractions in human sera. (1985) (38)
Normal Vascular Function Despite Low Levels of High-Density Lipoprotein Cholesterol in Carriers of the Apolipoprotein A-IMilano Mutant (2007) (37)
Analysis of Lupinus albus storage proteins by two-dimensional electrophoresis and mass spectrometry. (2005) (37)
Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. (2005) (37)
Cardiovascular Status of Carriers of the Apolipoprotein (2007) (37)
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. (2015) (37)
Effects of sub-chronic exposure to SO2 on lipid and carbohydrate metabolism in rats (1994) (37)
Reproducibility validation study comparing analog and digital imaging technologies for the measurement of intima-media thickness. (2000) (36)
Nutraceuticals for blood pressure control (2015) (36)
Liver-specific deletion of the Plpp3 gene alters plasma lipid composition and worsens atherosclerosis in apoE−/− mice (2017) (36)
Waist-to-height ratio is a highly sensitive index for the metabolic syndrome in a Mediterranean population. (2009) (36)
Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in healthy volunteers (2004) (36)
Increased plasma and aortic triglycerides in rabbits after acute administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin. (1984) (35)
Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits. (1982) (35)
Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. (1995) (35)
Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals (2018) (34)
Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP). (2021) (34)
Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial. (1988) (33)
Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials (2018) (33)
Prolonged retention of doubly labeled phosphatidylcholine in human plasma and erythrocytes after oral administration (1992) (33)
Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials (2018) (32)
ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials (2019) (32)
Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-IMilano (2003) (32)
Relation between the HDL apoproteins and AI isoproteins in subjects with the AIMilano abnormality. (1981) (32)
A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. (2009) (32)
Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDL. (2001) (32)
Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. (1978) (32)
Changes in high-density lipoprotein subfraction distribution and increased cholesteryl ester transfer after probucol. (1988) (32)
Diet, lipids and lipoproteins in patients with peripheral vascular disease (1974) (31)
Effects of smoking regular or light cigarettes on brachial artery flow-mediated dilation. (2013) (31)
Apolipoprotein A-IMilano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart. (2008) (31)
Cholesterol-lowering effect of dietary Lupinus angustifolius proteins in adult rats through regulation of genes involved in cholesterol homeostasis. (2012) (31)
Soy proteins reduce progression of a focal lesion and lipoprotein oxidiability in rabbits fed a cholesterol-rich diet. (2003) (31)
Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia. (1987) (30)
Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases (2016) (30)
Treatment with low dose metformin in patients with peripheral vascular disease. (1992) (30)
Characterization of A-I-containing lipoproteins in subjects with A-I Milano variant. (1988) (30)
Increased Apoprotein B in Very Low Density Lipoproteins of Patients with Peripheral Vascular Disease (1982) (29)
High density lipoprotein-3 heterogeneity in subjects with the apo-AIMilano variant. (1982) (29)
Enantioselective liquid chromatographic-electrospray mass spectrometric assay of beta-adrenergic blockers: application to a pharmacokinetic study of sotalol in human plasma. (2003) (29)
Lipid Lowering Drugs: Present Status and Future Developments (2021) (29)
Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits. (1984) (29)
Differential Expression of Ubiquitous and Neuronal Kinesin Heavy Chains During Differentiation of Human Neuroblastoma and PC12 Cells (1996) (29)
The effect of statin therapy on endoplasmic reticulum stress (2018) (28)
Effect of n‐3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: A double‐blind pilot study in primary prevention (2006) (28)
Omega-3 fatty acids selectively raise high-density lipoprotein 2 levels in healthy volunteers. (1991) (27)
High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice. (1997) (26)
Alterations in high-density lipoprotein subfractions during postprandial lipidaemia induced by fat with and without ethanol. (1988) (26)
Increased postprandial lipemia in Apo A-IMilano carriers. (1993) (26)
Lipoprotein(a): Knowns, unknowns and uncertainties. (2021) (26)
Studies on the mechanism of the cholesterol lowering activity of soy proteins (1990) (26)
Soy Milk with a High Glycitein Content Does Not Reduce Low-Density Lipoprotein Cholesterolemia in Type II Hypercholesterolemic Patients (2002) (26)
Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. (1987) (26)
Diets rich in saturated, monounsaturated and polyunsaturated fatty acids differently affect plasma lipids, platelet and arterial wall eicosanoids in rabbits. (1986) (26)
Influence of serum triglycerides on the HDL pattern in normal subjects and patients with coronary artery disease. (1990) (26)
Fraudulent (and non fraudulent) fatty acids for human health (1993) (26)
Effect of the combinations between pea proteins and soluble fibres on cholesterolaemia and cholesterol metabolism in rats. (2013) (25)
Pharmacological profile of BR-931, a new hypolipidemic agent that increases high-density lipoproteins. (1978) (25)
An Immunomodulating Fatty Acid Analogue Targeting Mitochondria Exerts Anti-Atherosclerotic Effect beyond Plasma Cholesterol-Lowering Activity in apoE-/- Mice (2013) (24)
Rosuvastatin does not affect human apolipoprotein A‐I expression in genetically modified mice: a clue to the disputed effect of statins on HDL (2011) (24)
Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. (2004) (24)
Lipid effects of celiprolol, a new cardioselective β‐blocker, versus propranolol (1989) (24)
Mechanisms of lipid-lowering agents. (1991) (23)
Apolipoprotein A‐IMilano: Correlation between High Density Lipoprotein Subclass Distribution and Triglyceridemia (1987) (23)
Apheretic treatment of severe familial hypercholesterolemia: comparison of dextran sulfate cellulose and double membrane filtration methods for low density lipoprotein removal. (1988) (23)
Inhibition of antipyrine metabolism by low‐dose contraceptives with gestodene and desogestrel (1991) (23)
Apolipoprotein A-II modulates HDL remodeling in plasma. (1992) (22)
Platelet α2‐adrenergic receptors in hypercholesterolemia: Relationship between binding studies and epinephrine‐induced platelet aggregation (1997) (22)
Increased total and high density lipoprotein cholesterol with apoprotein changes resembling streptozotocin diabetes in tetrachlorodibenzodioxin (TCDD) treated rats. (1980) (22)
L-homoarginine administration reduces neointimal hyperplasia in balloon-injured rat carotids (2016) (22)
Acute effects of high-density lipoproteins: biochemical basis and clinical findings (2008) (22)
Th-W55:4 Lupin proteins in the treatment of hypercholesterolemia (2006) (22)
Recent advances in synthetic pharmacotherapies for dyslipidaemias (2019) (22)
Cardiovascular risk changes after lipid lowering medications: are they predictable? (2000) (21)
Apolipoprotein A‐I breakdown is induced by thrombolysis in coronary patients (2007) (21)
Microsomal transfer protein (MTP) inhibition—a novel approach to the treatment of homozygous hypercholesterolemia (2014) (21)
Lupin (Lupinus albus) Protein Isolate (L-ISO) Has Adequate Nutritional Value and Reduces Large Intestinal Weight in Rats after Restricted and ad libitum Feeding (2007) (21)
HDL and the progression of atherosclerosis: new insights (2006) (21)
Dose-related increase of HDL-cholesterol levels after N-acetylcysteine in man. (1993) (21)
Tolerability of fibric acids. Comparative data and biochemical bases. (1992) (20)
SOYBEAN-PROTEIN DIET AND PLASMA-CHOLESTEROL (1977) (20)
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP) (2022) (20)
Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. (2015) (20)
Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients : a randomised controlled trial (2017) (20)
Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. (1997) (20)
Effects of Vegetable Proteins on Hypercholesterolemia and Gut Microbiota Modulation (2018) (20)
Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. (2018) (20)
Clinical relevance of drugs affecting tryptophan transport. (1975) (20)
Side effects of statins-from pathophysiology and epidemiology to diagnostic and therapeutic implications. (2022) (20)
Recombinant apolipoprotein A-I[Formula: See Text]: a novel agent for the induction of regression of atherosclerotic plaques (2003) (20)
Use of recombinant apolipoproteins in vascular diseases: the case of apoA-I. (2002) (20)
High-Density Lipoprotein Function Is Reduced in Patients Affected by Genetic or Idiopathic Hypogonadism. (2019) (20)
The binding of 2,3,7,8-tetrachlorodibenzodioxin to plasma lipoproteins may delay toxicity in experimental hyperlipidemia. (1983) (19)
Nutraceutical approaches to metabolic syndrome (2017) (19)
High-performance liquid chromatographic determination of ribavirin in serum and urine and of its urinary metabolite 1,2,4-triazole-3-carboxamide. (1987) (19)
Turnover and aortic uptake of very low density lipoproteins (VLDL) from hypercholesteremic rabbits as a model for testing antiatherosclerotic compounds. (1976) (19)
Pravastatin effectively lowers LDL-cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern (1994) (19)
Evaluation of a soft atherosclerotic lesion in the rabbit aorta by an invasive IVUS method versus a non-invasive MRI technology. (2004) (19)
Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. (2018) (18)
Recognition of patients with cardiovascular disease by artificial neural networks (2004) (18)
MECHANISM OF ACTION OF CLOFIBRATE (1981) (18)
The metabolic syndrome predicts carotid intima-media thickness no better than the sum of individual risk factors in a lipid clinic population. (2010) (18)
Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-I(Milano). (1998) (18)
Reduced biliary sterol output with no change in total faecal excretion in mice expressing a human apolipoprotein A‐I variant (2012) (18)
Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia (2006) (18)
Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches (2021) (18)
Bioequivalence of two omega-3 fatty acid ethyl ester formulations: a case of clinical pharmacology of dietary supplements. (2012) (17)
Plasma cysteine and glutathione are independent markers of postmethionine load endothelial dysfunction. (2007) (17)
NAFLD or MAFLD diagnoses and cardiovascular diseases: from epidemiology to drug approaches. (2021) (17)
Accelerated early catabolism of very low density lipoproteins in rats after dietary soy proteins. (1985) (17)
Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term (2012) (17)
Association of lipoprotein(a) with atherothrombotic events and fibrinolytic variables. A case-control study. (1995) (17)
Plasma glucose and insulin responses to carbohydrate food (rice) with different thermal processing. (1987) (17)
Cardiovascular risk and testosterone – from subclinical atherosclerosis to lipoprotein function to heart failure (2021) (16)
High-density lipoprotein deficiency in genetically modified mice deeply affects skin morphology: A structural and ultrastructural study. (2015) (16)
Acute effects of ethanol, caffeine, or both on platelet aggregation, thromboxane formation, and plasma-free fatty acids in normal subjects. (1984) (16)
New microporous cholestyramine analog for treatment of hypercholesterolemia. (1978) (16)
Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-Hodgkin lymphoma. (2012) (16)
HDL therapy today: from atherosclerosis, to stent compatibility to heart failure (2019) (16)
Dietary animal proteins and cholesterol metabolism in rats. (1989) (16)
A web site for the Rat Serum Protein Study Group (1999) (16)
Nutritional and nutraceutical considerations for dyslipidemia (2007) (16)
Dissociation of the metabolic and cardiovascular effects of the beta-adrenergic blocker practolol1 (1972) (15)
Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach (2020) (15)
Therapeutic significance of hypolipidemic and antiatherosclerotic drugs (1977) (15)
Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment (2006) (15)
Abstract 16516: Sustained LDL-C Lowering and Stable Hepatic Fat Levels in Patients With Homozygous Familial Hypercholesterolemia Treated With the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide: Results of an Ongoing Long-Term Extension Study (2013) (15)
Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women. (1990) (15)
Expression of Neuronal Kinesin Heavy Chain Is Developmentally Regulated in the Central Nervous System of the Rat (1997) (15)
Time course of forearm arterial compliance changes during reactive hyperemia. (2001) (15)
Magnetic Resonance Imaging Visualization of Vulnerable Atherosclerotic Plaques at the Brachiocephalic Artery of Apolipoprotein E Knockout Mice by the Blood-Pool Contrast Agent B22956/1 (2014) (15)
Alterations in the HDL system after rapid plasma cholesterol reduction by LDL-apheresis. (1988) (14)
Long-term treatment with metformin in a large cohort of hyperlipidemic patients (1978) (14)
Subclinical atherosclerosis and its progression are modulated by PLIN2 through a feed‐forward loop between LXR and autophagy (2019) (14)
Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake. (2019) (14)
Clinical evaluation of simvastatin in patients with severe hypercholesterolemia (1989) (14)
Familial associations of lipids and lipoproteins in a highly consanguineous population: the Limone sul Garda study. (1985) (14)
Hyperinsulinemia secondary to chronic administration of mazindol and d‐amphetamine (1971) (14)
PCSK9 antagonists and inflammation. (2018) (14)
Management of lipoprotein-X accumulation in severe cholestasis by semi-selective LDL-apheresis. (1991) (14)
Effect of serum lipoproteins on the adenylate cyclase activity of rat liver plasma membranes. (1981) (13)
Differential effects of beclobrate on lipid/lipoprotein distribution in normal and hypercholesterolemic rats. (1990) (13)
Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. (1985) (13)
Bococizumab for the treatment of hypercholesterolaemia (2017) (13)
Aortic and coronary atheromatosis in a woman with severe hypercholesterolaemia without LDL receptor alterations. (1991) (13)
Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention (2011) (13)
Defective Hydroxylation of Phenformin as a Determinant of Drug Toxicity (1981) (13)
Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases (2016) (12)
Viability of developing CETP inhibitors. (2008) (12)
Denaturation and self-association of apolipoprotein A-I investigated by electrophoretic techniques. (1997) (12)
Platelet alpha 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation. (1997) (12)
The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity. (2021) (12)
TEXTURED SOY PROTEIN AND SERUM-CHOLESTEROL (1980) (12)
Effect of plasma cholesterol reduction by pravastatin on the functional properties of forearm arteries in hypercholesterolemic patients. (1999) (12)
Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism. Part 2. Metabolism of very low density lipoproteins in rabbits. (1976) (12)
Bococizumab for the treatment of hypercholesterolaemia (2017) (11)
Long-term fasting improves lipoprotein-associated atherogenic risk in humans (2021) (11)
Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. (2016) (11)
The soybean protein diet does not lower plasma cholesterol? (1981) (11)
Apolipoprotein A-I Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles. (1993) (11)
Analysis of the genetic variants associated with circulating levels of sgp130. Results from the IMPROVE study (2020) (11)
Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia (1998) (11)
Japan: are statins still good for everybody? (2006) (11)
Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis. (1983) (11)
Phenotyping of typeII and IV hyperlipoproteinemias by a simple, quantitative agarose gel lipoprotein electrophoresis. (1971) (11)
Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone-poor soy protein concentrate. (2008) (10)
Predictability of low‐density lipoprotein levels during apheretic treatment of hypercholesterolemia (1991) (10)
Proprotein Convertase Subtilisin Kexin Type 9 (2021) (10)
Treatment with omega-3 fatty acid ethyl esters in hyperlipoproteinaemias: comparative studies on lipid metabolism and thrombotic indexes. (1995) (10)
Effects of dietary soy protein on liver catabolism and plasma transport of cholesterol in hypercholesterolemic rats. (1981) (10)
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels. (1983) (10)
Abstract 4055: Effect of Lupin Protein (Lupinus albus) on Cardiovascular Risk Factors in Smokers with Mild Hypercholesterolemia (2006) (10)
Dyslipidemia and coronary heart disease (1996) (10)
Abstract: P1305 WAIST TO HEIGHT RATIO IS A HIGHLY SENSITIVE INDEX FOR THE METABOLIC SYNDROME IN A MEDITERRANEAN POPULATION (2009) (10)
Effects of omega 3 fatty acid ethyl esters on monocyte tissue factor expression. (1994) (10)
Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis (2019) (10)
Methotrexate for Cardiovascular Risk Reduction: The Right Choice? (2020) (10)
Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats. (1980) (10)
A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis. (2006) (9)
Effects of pantethine on different models of experimental hyperlipidemia in rodents: a comparison with clofibrate. (1982) (9)
Dubious benefits and potential risk of soy phyto-oestrogens (2000) (9)
Nutrient Metabolism Soy Protein Peptides Regulate Cholesterol Homeostasis in Hep G 2 Cells (2000) (9)
Prevalence of coronary heart disease risk factors in northern-Italian male and female employees. (1995) (9)
Reduced apoprotein B and increased lipoprotein turnover in cholesterol-fed rabbits after partial ileal bypass. (1981) (9)
Effect of hypolipidemic and hypoglycemic drugs on ethanol induced hypertriglyceridemia in rats. (1977) (9)
In vitro activity of probucol on cholesteryl ester transport. (1990) (8)
PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies (2019) (8)
Consensus: Hypertriglyceridaemia as a vascular risk factor (1990) (8)
Structural features and dynamics properties of human apolipoprotein A-I in a model of synthetic HDL. (2009) (8)
Inhibition of amphetamine tolerance and metabolism by propranolol. (1974) (8)
Magnetic Resonance Imaging Visualization of Vulnerable Atherosclerotic Plaques at the Brachiocephalic Artery of Apolipoprotein E Knockout Mice by the Blood-Pool Contrast Agent B22956/1. (2014) (8)
Therapeutic use of the high-density lipoprotein protein and peptides (2006) (8)
Influences of lipid-modifying agents on hemostasis (1993) (8)
Metabolism of HDL2 and HDL3 cholesterol by monolayers of rat hepatocytes (1981) (8)
Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. (2007) (8)
Size is a major determinant of dissociation and denaturation behaviour of reconstituted high-density lipoproteins. (2002) (8)
Low density lipoprotein (LDL) receptor activity is modulated by soybean globulins in cell culture (1992) (8)
Effects of EPA and DHA ethylesters on plasma fatty acids and on platelets, PMN and monocytes in healthy volunteers. (1991) (8)
Human apolipoprotein A-II inhibits the formation of pre-beta high density lipoproteins. (1996) (8)
Relationship between fibrinolytic and metabolic variables: a study in patients attending a lipid clinic (2000) (7)
Increased plasma cholesterol and decreased body lipid levels in Wistar rats following pirinixil (BR 931) treatment. (1979) (7)
Influence of body variables in the development of metabolic syndrome—A long term follow-up study (2018) (7)
Plasma tryptophan transport in normal and depressed subjects. (1975) (7)
Control of human and animal platelet aggregation by a new prostacyclin analog. (1985) (7)
Selective and semiselective low-density lipoprotein apheresis in familial hypercholesterolemia. (1988) (7)
Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed. (2010) (7)
Cholesteryl ester transfer protein antagonism by drugs--a poor choice. (2010) (7)
Apolipoprotein AIMilano. (The first molecular variant of human apolipoproteins). (1982) (7)
Indobufen treatment in type IIA hypercholesterolemic subjects: effects on platelet function and malondialdehyde production. (1981) (7)
Structural and dynamic features of apolipoprotein A-I cysteine mutants, Milano and Paris, in synthetic HDL. (2010) (7)
Soy protein components active in the regulation of cholesterol homeostasis. (2001) (7)
Impact of cigarette smoking on the plasma fatty acid profile and their interaction in determining the burden of subclinical atherosclerosis (2014) (7)
Correlation of parents' longevity with carotid intima-media thickness in patients attending a Lipid Clinic. (2005) (7)
Long-Term Efficacy and Safety of Lomitapide for the Treatment of Homozygous Familial Hypercholesterolemia: Results of the Phase 3 Extension Trial † (2015) (6)
Non‐invasive assessment of unstimulated forearm arterial compliance in human subjects. Impaired vasoreactivity in hypercholesterolaemia (1995) (6)
Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (2021) (6)
Iron‐ovotransferrin preparation does not interfere with ciprofloxacin absorption (1996) (6)
NOVEL PYRIMIDINE AND 1,3,5-TRIAZINE HYPOLIPEMIC AGENTS (1985) (6)
Activity profile of gemfibrozil on the major plasma lipoprotein parameters (1992) (6)
OMEGA-3 AND CARDIOVASCULAR PREVENTION - IS THIS STILL A CHOICE? (2022) (6)
Novel derivatives of 3α,7α-dihydroxy-5β-cholan-24-OIC acid (chenodeoxycholic acid) and 3α,7β-dihydroxy-5β-cholan-24-OIC acid (ursodeoxycholic acid) (1986) (6)
New strategies in the development of anti-atherosclerotic drugs. (1980) (6)
Lipid effects of celiprolol, a new cardioselective beta-blocker, versus propranolol. (1989) (6)
Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells (2021) (6)
Carotid IMT and atherosclerosis: "Calling things by name". (2020) (6)
Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs. (1981) (6)
Barbiturate metabolism as affected by neoplastic disease. (1971) (6)
New targets for lipid lowering and atherosclerosis prevention. (1995) (6)
Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS): A protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects (1993) (6)
Cimetidine increases HDL-cholesterol, particularly in the HDL3 subfraction. (1985) (6)
The use of echocardiography for the non-invasive evaluation of coronary artery disease (2017) (5)
Influence of clofibrate on serum triptophan in man (1974) (5)
Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer. (2009) (5)
Can we further optimize statin therapy to increase tolerability? (2019) (5)
Effects of lipid lowering agents and other treatment regimens on serum lipoproteins (1990) (5)
Mechanisms of action of absorbable hypolipidemic drugs. (1985) (5)
Lipoprotein structure in male subjects during in vivo lipolysis: effect of an anti-lipolytic treatment with acipimox. (1993) (5)
The Role of High-Density Lipoprotein Cholesterol in 2022 (2022) (5)
Cholesterol and bile-acid metabolism in normal and cholesterol-fed rabbits after partial ileal bypass. (1982) (5)
CETP levels rather than polymorphisms as markers of coronary risk: healthy athlete with high HDL-C and coronary disease--effectiveness of probucol. (2006) (5)
[Clinical trial of tibric acid, a new hypolipidemic agent]. (1974) (5)
Cyclic 3'5'-AMP, its dibutyryl derivative and theophylline effects on the rat portal vein in vitro. (1970) (5)
Consensus: hypertriglyceridaemia as a vascular risk factor. The Italian Group for the Study of Metabolic Diseases and Arteriosclerosis. (1990) (4)
Status and potential clinical value of a transthoracic evaluation of the coronary arteries (2015) (4)
Pathogenetic mechanisms of the endogenous hypertriglyceridemia in a nonobese rat model. (1986) (4)
Metabolic approach to the diagnosis and treatment of atherosclerotic peripheral vascular disease. (1987) (4)
Hyperresponsiveness to dietary cholesterol in inbred rabbits is not associated with enhanced reduction in binding of beta-VLDL to liver membranes. (1992) (4)
Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients (2004) (4)
Left main coronary wall thickness correlates with the carotid intima media thickness and may provide a new marker of cardiovascular risk (2018) (4)
Dietary Effects on Lipoprotein Composition (1978) (4)
Clinical evaluation of tibric acid (CP 18,524) a new hypolipidemic agent. (1974) (4)
PCSK9 in HIV infection: New opportunity or red herring? (2019) (4)
Bempedoic Acid: for Whom and When (2022) (4)
[Treatment of hyperlipidemia type II with soybeans]. (1979) (4)
The unexpected roles of extracellular ADP and P2Y13 receptor in reverse cholesterol transport (2010) (4)
MICROPOROUS CHOLESTYRAMINE IN SUSPENSION FORM (1982) (4)
patients reduces tissue factor activity in adherent monocytes. n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic (2012) (4)
Effects of fatty acid esters of cheno- and ursodeoxycholic acids on gallstone formation in hamsters. (1986) (4)
Glycosaminoglycans inhibit the aortic uptake of very low density lipoproteins in rabbits. (1979) (4)
Gender differences in lipoprotein(a) concentration as predictors of coronary revascularization in patients with known coronary artery disease. (2020) (4)
The FIELD study (2006) (4)
Glucagon release following experimental diets in man: effects of soybean and casein enriched diets. (1982) (4)
Endogenous hypertriglyceridemia in a nonobese rat model: plasma lipoproteins and dietary sensitivity. (1986) (4)
Drugs, lipids and atherosclerosis. (1975) (4)
Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. (2022) (4)
Human Apolipoprotein Mutants 2 (1989) (4)
Obesity and thrombotic risk (2010) (4)
Development of a model based on body composition to predict drug kinetics; II. Application of the model to the use of digoxin in elderlies. (2004) (4)
Abstract 17396: Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia (2012) (4)
Oral polyunsaturated phosphatidylcholine reduces platelet lipid and cholesterol contents in healthy volunteers (1985) (4)
Fish, long-chain omega-3 polyunsaturated fatty acids, and cardiovascular disease (2008) (4)
Antiapolipoprotein B cryoglobulinemia associated with normal plasma lipids and severe atherosclerosis. (1986) (4)
n-3 Fatty Acids: Incorporation into Tissue Lipids and Interactions with Dietary Components (1992) (3)
PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells (2022) (3)
Efficacy of cholestyramine does not vary when taken before or during meals. (1991) (3)
Increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia (1990) (3)
Vegetable proteins as drugs. (1987) (3)
Lipid‐lowering therapy of everolimus‐related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) (2018) (3)
ApoA‐IMilano from structure to clinical application (2008) (3)
Metabolic effects of alcohol. (1979) (3)
Soy proteins, cholesterolemia, and atherosclerosis. (2006) (3)
Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study (1995) (3)
Correction: Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration (2018) (3)
CETP antagonism versus agonism in cardiovascular prevention and plaque regression (2009) (3)
Effects of probucol on the high density lipoprotein system in hypercholesterolaemic patients. (1989) (3)
Isoelectric focusing and immunoblotting of the platelet membrane glycoprotein complex IIb. IIIA following urea solubilization (1992) (3)
New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran (2021) (3)
Author Correction: Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials (2020) (3)
Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—Evidence from ApoE-/- Mice (2022) (3)
Apolipoprotein AI-Milano: altered lipid binding properties in a human apolipoprotein variant. (1988) (3)
The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis (2022) (3)
Novel derivatives of 3 alpha,7 alpha-dihydroxy-5 beta-cholan-24-oic acid (chenodeoxycholic acid) and 3 alpha,7 beta-dihydroxy-5 beta-cholan-24-oic acid (ursodeoxycholic acid). (1986) (3)
Interactions between carbonic anhydrase and its inhibitors revealed by gel electrophoresis and circular dichroism (2000) (3)
Drugs and Atherosclerosis (1977) (2)
Lupin protein (Lupinus albus) intake decrease blood pressure and other cardiovascular risk factors in smokers. A pilot study (2007) (2)
Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open-label interventional study (2023) (2)
Apolipoproteins as “Drugs”: Current Status (1993) (2)
Acceptability of lupin protein products in healthy competitive athletes (2008) (2)
In Vivo Catabolism of Apolipoprotein A-I in Subjects with Familial Hypoalphalipoproteinemia (1989) (2)
A salmon protein hydrolysate excerts lipid-independent anti-atherosclerotic activity in apoe-deficient mice (2014) (2)
Automatic identification of variables in epidemiological datasets using logic regression (2017) (2)
Differential Effects of Red Yeast Rice, Berberis Aristata and Morus Alba Extracts, Active Components of LopiGLIK®, on PCSK9 in HepG2 Cells (2018) (2)
[Separation of high density lipoproteins (HDL) using zonal ultracentrifugation in patients with apolipoprotein AI Milano variant]. (1983) (2)
Both gestodene and desogestrel containing oral contraceptives reduce antipyrine clearance by impairing microsomal oxidative metabolism (1990) (2)
Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. (1997) (2)
Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients. (2017) (2)
Experience with a drug formulary in a large Italian city hospital. (1989) (2)
Beclobrate : a new lipoprotein regulator (1990) (2)
Clinical evaluation of MK-185: A new hypolipidemic drug (1972) (2)
Soybean Protein Diet in the Treatment of Hypercholesterolemia (1977) (2)
Professor C.R. Sirtori replies (1983) (2)
Treatment and reversal of atherosclerosis with drugs (1978) (2)
Reduced platelet aggregability and increased vascular prostacyclin formation in a variant rat strain (IVA-SIV) with endogenous hypertriglyceridemia. (1988) (2)
Apolipoprotein A-IMilano: In Vivo Metabolism of an Apolipoprotein A-I Variant (1986) (2)
Mechanism of action of hypolipidemic drugs. (1975) (2)
Human Apolipoprotein Mutants 2: From Gene Structure to Phenotypic Expression (1989) (2)
Enhanced Platelet Aggregation And Arachidonic Acid Metabolism Associated To Reduced Sensitivity To Exogenous Prostacyclin In Hypercholesterolemic Subjects (1981) (2)
ApoA-I depletion in chow-fed ApoEKO mice severely worsens coronary atherosclerosis development (2016) (2)
Metabolic Regulation of SARS-CoV-2 Infection (2021) (2)
Lipids, lipoproteins, obesity and the cardiovascular risk, what is new and what has been left aside. (1997) (2)
A New Noninvasive Method for the Accurate and Precise Assessment of Varicose Vein Diameters (2003) (2)
An experimental model for type V hyperlipoproteinemia: Combined tween and cholesterol treatment in rabbits (1973) (2)
Plasma lipids and coagulation in patients with arteriosclerotic dementia (1974) (2)
HRT and Correction of Lipoprotein Disorders (1994) (2)
New frontiers in atherosclerosis prevention and treatment: HDL as a novel therapeutic target (2004) (2)
Single dose pharmacokinetics of aminoglutethimide by a rapid SIM methodology. (1988) (2)
Obesity, weight loss, and pregnancy outcomes (2006) (2)
Development of a model based on body composition to predict drug kinetics-1 evaluation in healthy volunteers. (2004) (2)
Evaluation of lipoproteins/apolipoproteins as therapeutic agents for the treatment of vascular and nonvascular disease. (1998) (2)
Increased pulmonary residual volume in patients with hyperlipoproteinemias. (1977) (2)
Human Apolipoprotein Mutants (1986) (2)
Intake of food rich in saturated fat in relation to subclinical atherosclerosis and potential modulating effects from single genetic variants (2021) (2)
Mechanism of the plasma cholesterol lowering effect of tazasubrate in rats: accelerated plasma cholesterol transport with increased liver lipoprotein receptor activity. (1986) (2)
Evidence-based medicine criteria applied to hypolipidemic and antihypertensive drug trials: is drug efficacy always the same? (1998) (2)
Metabolic effects of alcohol : proceedings of the International Symposium on Metabolic Effects of Alcohol held in Milan (Italy) on June 18-21, 1979 (1979) (2)
ApoA-1 Milano and regression of atherosclerosis. (2004) (1)
Apolipoprotein AI-Milano: A Structural Modification in an Apolipoprotein Variant Leading to Unusual Lipid Binding Properties (1986) (1)
Long lasting effects of administration of an EPA and DHA enriched preparation on haemostatic variables (1992) (1)
In Vitro Transformation of Cheno- and Ursodeoxycholic Acids and Their 7-Oleyl Esters by Human Intestinal Microflora (1988) (1)
Pantethine Treatment in Type III Hyperlipoproteinemia (1987) (1)
Changes in hemostatic variables following administration of an EPA and DHA enriched preparation (1992) (1)
PCSK9 Inhibition and Risk of Diabetes: Should We Worry? (2022) (1)
Comparison of dextran sulphate cellulose and double filtration plasmaphereses for the treatment of severe hypercholesterolemia. (1988) (1)
Evaluation of Transthoracic Echocardiography in the Assessment of Atherosclerosis of the Left Main Coronary Artery: Comparison with Optical Frequency Domain Imaging (a Pilot Study) (2021) (1)
Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients. (1996) (1)
Limited conformational flexibility of a disulfide-linked apolipoprotein A-I dimer in reconstituted high density lipoproteins (1997) (1)
Effect of statin therapy on plasma apolipoprotein C-III concentrations: a Systematic Review and Meta-Analysis of Randomized Controlled Trials (2018) (1)
A new approach to the investigation of drugs affecting lipoproteins. (1978) (1)
Experimental studies on nutrition, hypertension, and cardiovascular diseases. (1983) (1)
Hypolipidemic drugs. (1973) (1)
Placental transfer of sulfanilamide as determined at constant drug concentrations in the maternal blood. (1971) (1)
Effect of Hypocholesteremic Agents on an Experimental Brain Tumor in Mice (1969) (1)
W07-O-002 Increased ABCA1-mediated cholesterol efflux potential of sera from Apoa-I Milano carriers (2005) (1)
1.P.89 Mechanism of hypertriglyceridemia in human apolipoprotein A-IMilano transgenic mice (1997) (1)
Asymptomatic EBV Infection may Uncover Ezetimibe Liver Alterations in a Hypercholesterolemic Child (2013) (1)
A ‘drug’ for the prevention of atherosclerosis in vegetable proteins? (1982) (1)
Effect of pivagabine on stress-induced gastric ulcer formation in rats. (1997) (1)
Large waist circumference with normal BMI identifies a significant subset of Italian female patients with the metabolic syndrome--a high risk presentation? (2009) (1)
Soy protein diet supplementation reduces LDL cholesterol in severely hypercholesterolemic patients (1997) (1)
[Pharmacological control of heart rate]. (1994) (1)
APOLIPOPROTEIN-SPECIFIC HIGH DENSITY LIPOPROTEIN POPULATIONS IN PLASMA OF CARRIERS OF THE APOLIPOPROTEIN AI-MILANO (1989) (1)
An interchain disulfide bridge strikingly alters the structure/function of apolipoprotein A-I (1994) (1)
[Diet therapy with soya (Cholsoy) in primary hypercholesteremia]. (1978) (1)
Drugs Affecting Thrombosis and Atherosclerosis (1993) (1)
Apoprotein Changes Following Treatments with Hypolipidemic Drugs (1980) (1)
From Genome Wide Association Study to arterial wall protection : homoarginine effect on intimal hyperplasia in balloon-injured rat carotids (2017) (1)
Inherited atherogenic dyslipidemias: are they correctly reported? (2020) (1)
Diet and Atherosclerosis (1975) (1)
Human apolipoprotein mutants III : diagnosis and treatment (1993) (1)
Brain-Derived Neurotrophic Factor and Extracellular Vesicle-Derived miRNAs in an Italian Cohort of Individuals With Obesity: A Key to Explain the Link Between Depression and Atherothrombosis (2022) (1)
Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening in hypercholesterolemic rabbits (1994) (1)
Soya-enriched mixed diet significantly improves cardiovascular and metabolic risk factors: A randomized controlled trial (2016) (1)
Effect of tetranectin-apoa-i infusions on atherosclerosis progression/regression in rabbit carotid arteries (2014) (1)
High-density lipoprotein: therapeutic target, 1 year on (2007) (1)
Senility and molecular suicide. (1984) (1)
2910 – DISPOSITION OF METFORMIN (N, N-DIMETHYLBIGUANIDE) IN MAN (1978) (1)
Desirable Lipoprotein Parameters in Early Drug Trials (1987) (1)
Increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia (2005) (1)
Effects of cigarette smoking on the relationship between fatty acids and subclinical atherosclerosis (2010) (1)
Correlations of n-3 (omega-3) fatty acid levels with lipoproteins: negative correlation with HDL-C after an oral load (2013) (1)
[Beta-blocking activity of the 2 isomers and of the racemic form of INPEA (N-isopropyl-p-nitrophenylethanolamine) on the isolated portal vein in the rat]. (1969) (0)
P286 DIFFERENTIAL LIPID/LIPOPROTEIN RESPONSE IN WOMEN VS MEN IN PRIMARY AND SECONDARY PREVENTION TREATED WITH STATINS (2010) (0)
PARENTS’ LONGEVITY AS PREDICTOR OF CAROTID ATHEROSCLEROSIS (2002) (0)
Liver-specific deletion of lipid phosphate phosphatase 3 exacerbates atherosclerosis in apoE-KO mice (2014) (0)
C18 Statins, not fibrates, enhance the production of long chain polyunsaturated fatty acids in monocytic cells and in humans (1999) (0)
Contents, Vol. 29, 1985 (1985) (0)
Hypoplastic Left Anterior Descending Coronary: Early Assessment by Transthoracic Coronary Ultrasound (2018) (0)
Th-W55:3 Lupin protein: A new source of cardiovascular protective agents? (2006) (0)
[The treatment of hypercholesterolemia in primary and secondary prevention]. (1995) (0)
Genetic characterization of LDL-receptor in patients with a clinical diagnosis of familial hypercholesterolemia: two novel mutations (2014) (0)
Sex-Related Differences in the Phenotypic Expression of the Apolipoprotein A-IMilano Mutant (1993) (0)
19 LIGHT AND REGULAR CIGARETTES CONSUMERS AND ENDOTHELIAL DYSFUNCTION (2008) (0)
Turnover and aortic uptake of very low density lipoproteins (VLDL) from hypercholesteremic rabbits: effect of metformin. (1977) (0)
Experimental and clinical studies on the cholesterol lowering activity of the soybean protein diet (1982) (0)
Isoflavones and postmenopausal women. (2004) (0)
Subject Index, Vol. 29, 1985 (1985) (0)
[Study of metformin in experimental arteriosclerosis (plasma lipoproteins, platelets, arteries and the pancreas)]. (1977) (0)
[Pharmacologic treatment with statins]. (1999) (0)
Spontaneous Hypertriglyceridemia in a Non-Obese Rat Model: The IVA-SIV Rat (1987) (0)
Genetics of CETP Deficiency-Associated Cardiovascular Risk (2008) (0)
1 Differential effects of red yeast rice , Berberis aristata 2 and Morus alba extracts , active components of 3 LopiGLIK ® , on PCSK 9 in HepG 2 cells 4 (2018) (0)
4.P.330 Apolipoprotein A-I structure modification differently effect LCAT activation and cholesterol efflux (1997) (0)
The AI-Milano HDL Particles (1986) (0)
86 A NEW SPLICING MUTATION OF LPL GENE IN AN HYPERCHYLOMICRONEMIC PATIENT WITH RECURRENT PANCREATITIS (2008) (0)
THE PLATELET ANTIAGGREGATORY EFFECT OF ILOPROST IS ENHANCED BY ASPIRIN:IN VITRO AND EX VIVO STUDIES IN HUMAN SUBJECTS. (1987) (0)
Isoflavones and postmenopausal women. Authors' reply (2004) (0)
Recombinant Apolipoprotein A-IMllano for the Treatment of Vascular Disease (1996) (0)
Abstract 411: Vasculoprotective Function of HDL from Cetp-deficient Subjects (2013) (0)
Pollution from fine particulate matter and atherosclerosis: A narrative review. (2023) (0)
Fibrates and the concept of fraudulent fatty acids (1994) (0)
Evaluation of nutritional and biological properties of a lupin protein isolate in sprague-dawley rats (2006) (0)
Causes Underlying the Reduced Response to Simvastatin Treatment in Hypercholesterolemic Patients (1993) (0)
AI Milano — History and Clinical Profile (1986) (0)
Familial disorders of plasma apolipoproteins (1985) (0)
Intima media thickness and vascular risk factors for the recognition of patients at high risk of atherosclerosis (2001) (0)
MS392 MORE UNIFORM CHOLESTEROLEMIC RESPONSE OF WOMEN VS MEN WHEN USING A DIVERSIFIED DRUG APPROACH TO HYPOLIPIDEMIC THERAPY (2010) (0)
Effect of trans-1,4-bis-2-dichlorbenzyl-aminoethyl-cyclohexane (AY-9944) on the experimental brain tumor G26A. (1972) (0)
Tu-W23:7 Effect of high cholesterol diet on cholesterol and bile acid metabolism in A-IM and A-I transgenic mice (2006) (0)
Genetic and phenotypic characterization of LDL-receptor in patients with a clinical diagnosis of familial hypercholesterolemia: Two novel mutations (2016) (0)
Biochemical and Molecular Actions of Nutrients A Proteomic Investigation of Isolated Soy Proteins with Variable Effects in Experimental and Clinical Studies 1 (2002) (0)
Impact of dietary treatments on the lipidomic profile of plasma, aorta and liver from ldlr-ko and pcsk9-ko mice (2014) (0)
Letters to the EditorALCOHOLIC HYPERLIPIDÆMIA (1972) (0)
Effect of Supplementation with Moderate Doses of N-3 Fatty Acid Ethyl Esters to Hypertriglyceridemic Patients on Lipid and Hemostatic Variables (1995) (0)
Chapter 3: Mechanism of the differential hypercholesterolemic effect of dietary casein and fish protein. (1991) (0)
24 SENSITIVE BIOMARKER FOR STATIN-INDUCED MYOTOXICITY (2011) (0)
Drugs Affecting HDL/Triglyceride Levels (1992) (0)
Cholesterol-Lowering and High-Density Lipoprotein-Raising Properties of Lecithinated Soy Proteins in Type II Hyperlipidemic Patients (1987) (0)
Dipyridamole treatment in chronic obstructive airways disease: Effect on platelet regeneration time (2004) (0)
Inhibition of smooth muscle cell proliferation by sera of fluvastin treated subjects with type IIa hypercholesterolemia (1995) (0)
EFFECTS OF ATORVASTATIN ON THE FUNCTIONAL PROPERTIES OF FOREARM ARTERIES IN HYPERCHOLESTEROLEMIC PATIENTS (2002) (0)
Normal endothelial function in carriers of the apolipoprotein A-IMilano mutant despite low HDL-cholesterol levels (2007) (0)
Different activity profile of β‐cyclodextrin and hydroxypropyl‐β‐cyclodextrin in hyperlipidemic animal models (2007) (0)
Platelet alpha2-adrenoceptors density in hypercholesterolemia. Relationship with platelet sensitivity to epinephrine (1997) (0)
ApoA-I deficiency in apoe-ko mice severely alters lymph nodes and modulates T lymphocyte subsets (2014) (0)
[48] HDL FROM CARRIERS OF THE R37X MUTATION IN CETP GENE AND ENDOTHELIAL CELL HOMEOSTASIS (2009) (0)
Effect of n-3 fatty acids on carotid atherosclerosis and hemostasis in hypertriglyceridemic patients: a double blind pilot study in primary prevention (2005) (0)
The Intima Media Thickness (2000) (0)
4.P.351 Cholesteryl ester transfer rate (CETR) is a major factor in the regulation of HDL remodeling in the plasma of obese subjects (1997) (0)
Non-STEMI from a Hypoplastic Left Anterior Descending Coronary: Earlier Assessment by Transthoracic Coronaryultrasound Evaluation (2017) (0)
Statin Intolerance Can be Monitored by Plasma Eicosanoid Assays (2013) (0)
N-3 Fatty Acid Ethyl Esters Lower Triglyceridemia without Increasing the Diabetic Risk: Italian Fish Oil Multicenter Study (1996) (0)
B-mode imaging and intima media thickness: analog VS digital technologies (1999) (0)
Clofibrate affects plasma tryptophan transport: Possible antidepressant implications (1974) (0)
Triglyceride-Rich Lipoproteins: Role in Atherogenesis and Haemostasis (1993) (0)
Gemfibrozil treatment in type II hyperlipoproteinemia changes in LDL subclass distribution and LDL interaction with cells (1994) (0)
Evaluation of the health benefits of soy protein consumption in patients carrying the metabolic syndrome (2015) (0)
Lipidomics of plasma, liver and aorta of Pcsk9-KO mice (2016) (0)
Acknowledgement to the 2006 Reviewers (2007) (0)
Th-W53:7 Effect of omega-3 PUFA on carotid IMT and haemostasis in hypertrigly ceridemic patients: A longitudinal pilot study in primary prevention (2006) (0)
Tu-P9:343 Smoking habits as determinant of carotid IMT in gender specific models (2006) (0)
PCSK9, SINDROME METABOLICA E DIABETE (2017) (0)
[The physiopathology and pharmacological approach to multiple metabolic and blood coagulation syndromes, the characteristics of atherogenesis]. (1991) (0)
Cardiovascular determinants of QT interval duration in dysplipidemic patients in primary prevention in two genders (2013) (0)
Mutants of apolipoproteins A and C. (1986) (0)
Novel Therapeutic Approaches to Insulin Resistance/Diabetic Dyslipidemia (1998) (0)
76 MR IMAGING OF ATHEROSCLEROTIC PLAQUES IN BRACHIOCEPHALIC ARTERIES OF APOLIPOPROTEIN E KNOCKOUT MICE (2008) (0)
New derivatives of chenodeoxycholic (1982) (0)
PCSK9 e aterosclerosi: solo LDL colesterolo? = PCSK9 and atherosclerosis: effects beyond LDL cholesterol (2017) (0)
Apolipoproteins in the Treatment of Vascular and Nonvascular Disease (1995) (0)
Placental transfer of drugs. IV. Placental transfer of chlorpromazine, pentobarbital and phenylbutazone with fetal electrocardiographic changes as determined by direct lead tracing. (1971) (0)
Liver-specific deletion of the PPAP2B gene worsens atherosclerosis in apoE-/- mice (2015) (0)
Erratum to: The unexpected roles of extracellular ADP and P2Y13 receptor in reverse cholesterol transport (2011) (0)
Present status of clinical pharmacology in Italy (1974) (0)
Plasma Lipoprotein Changes Induced by Diets and Drugs (1982) (0)
Changes in high density lipoprotein subfraction distribution and increased cholesteryl ester transfer after probucol (1988) (0)
Apolipoprotein A-I and the molecular variant A-IM: evaluation of the antiatherogenic effect in a transgenic model (2002) (0)
Meeting Summary Lipoproteins and Coronary Atherosclerosis (2005) (0)
Dietary and biochemical studies with textured soy proteins (1987) (0)
Early efficacy and safety studies. (1998) (0)
4.P.85 Long term treatment with ethyl esters of N-3 fatty acids in hypertriglyceridemic patients with glucose intolerance (1997) (0)
98 HYPOLIPIDEMIC EFFECT OF DIETARY LEGUME PROTEINS: IMPACT ON GENES REGULATING HEPATIC LIPID METABOLISM (2008) (0)
New dietary proteins for cholesterol control : lupin and hempseed (2019) (0)
Glycosylation pattern of platelet glycoprotein IIb and IIIa in type IIa hypercholesterolemia. (1994) (0)
Does the Gene Encoding Apolipoprotein A-IMilano Protect the Heart? (2000) (0)
Lipoprotein (a): concentration, isoforms, polymorphisms and association with preclinical atherosclerosis (2015) (0)
NORMAL ENDOTHELlAL FUNCTION DESPlTE LOW HDL-CHOLESTEROL LEVELS IN CARRIERS OF THE APOLIPOPROTEIN A-IMitano MUTANT (2007) (0)
Lipid metabolism in mice expressing human apolipoprotein A-IMilano (1997) (0)
Lipid-lowering drugs (2018) (0)
Phospholipids and atherosclerosis Mechanistic and kinetic aspects (1993) (0)
Apolipoprotein E and Alzheimer’s Disease (1995) (0)
Hepatocyte-specific PPAP2B ablation increases plasma levels of several minor pro-atherogenic lipid species and worsens atherosclerosis in apoE-/- MICE (2016) (0)
EFFECT OF CIGARETTE SMOKING ON CAROTID IMT AND FRS (2007) (0)
We-W39:6 Effect of smoking habits on the relationships between atherosclerosis risk factors and carotid IMT (2006) (0)
Effects of Chenodeoxycholic Acid (CD) Treatment on Endogenous Plasma Triglyceride (TG) Transport in Hyperlipoproteinemia (HLP) (1978) (0)
Inherited atherogenic dyslipidemias: are they correctly reported? (2020) (0)
Tu-P9:336 Smoking habits as determinant of carotid IMT in patients in primary and secondary prevention (2006) (0)
Tu-P9:340 Chronic use of light or heavy cigarettes and carotid IMT (2006) (0)
Lipoprotein(a) is not predictive of ischemic events in atherosclerotic patients (1994) (0)
Effect of soy on metabolic syndrome and cardiovascular risk factors: Evidence from a randomized controlled trial (2017) (0)
Clinical response to probucol in hypercholesterolemia: peculiar sensitivity of different subpopulations (1996) (0)
Abstract: 105 INCREASED PLASMA CERAMIDES FOLLOW STATIN-INDUCED MUSCLE TOXICITY (2009) (0)
Comparative Evaluation of Olive Oil and of Corn Oil in the Prevention of Atherosclerosis (1987) (0)
Comments on the MRC/BHF Heart Protection Study (2003) (0)
Pivagabine (Tonerg). A novel psychoactive drugs. (1997) (0)
Hypercholesterolaemia treated bysoybean protein diet (2011) (0)
Properties of ApoA-I Milano (2005) (0)
HDL mutants and mimetics for the direct treatment of vascular disease (2000) (0)
Exogenous di-linoleyl phosphatidylcholine (PC) increases plasma and cell PC and selected linoleic acid pools in man*1 (1992) (0)
Reduced mammary tumor progression in a transgenic mouse model fed isoflavone-free soy protein concentrate (2004) (0)
Alcoholic hyperlipidaemia. (1972) (0)
Abstract: P371 A NOVEL MUTATION IN CETP GENE AS A CAUSE OF CETP DEFICIENCY IN A CAUCASIAN KINDRED (2009) (0)
Nicotinic acid and derivatives (1991) (0)
4.P.2 Pravastatin reduces carotid intima-media thickness progression also in patients showing an unsatisfactory response in terms of LDL-C reduction. The CAIUS study (1997) (0)
Relationship between cardiovascular global risk in primary and secondary prevention and carotid atherosclerosis (2004) (0)
A single infusion of trimeric apoA-I in hypercholesterolemic rabbits stabilizes atherosclerotic plaques and increases plasma cholesterol efflux capacity (2015) (0)
[24] ROSUVASTATIN DOES NOT AFFECT HUMAN APOLIPOPROTEIN A-I EXPRESSION IN GENETICALLY MODIFIED MICE A CLUE TO THE DISPUTED ACTIVITY OF STATINS ON HDL (2009) (0)
Beneficial effects of lupin proteins : a novel source of hypocholesterolemic agents? (2004) (0)
Lipoprotein structure in male subjects vivo lipolysis: effect of an anti-lipolytic with acipimox during in treatment (1993) (0)
Early efficacy and safety studies. Discussion (1998) (0)
We-P14:484 Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone-poor soy protein concentrate (2006) (0)
Tu-P8:300 Sera from patients treated with fluvastatin XL inhibit human arterial myocyte proliferation (2006) (0)
Plasma lipids andcoagulation inpatients with arteriosclerotic dementia (1974) (0)
Contents Vol. 50, 2006 (2007) (0)
DRUGS AFFECTING REVERSE CHOLESTEROL TRANSPORT (1993) (0)
Experience with Soybean Protein Diets in Treating Hypercholesterolemias (1983) (0)
Effects of Lipid Lowering Diets and of Bile Acid Sequestrants on Plasma Lipoproteins and Biliary Metabolism (1985) (0)
ARTIFICIAL NEURAL NETWORKS IN THE RECOGNITION OF PATIENTS AT HIGH RISK OF CARDIOVASCULAR DISEASE (2002) (0)
Pilot study of pirinixil (BR 931) in various forms of hyperlipoproteinemias. (1981) (0)
Platelet α2-adrenergic receptors density in hypercholesterolemia. Relationship with platelet sensitivity to epinephrine (1997) (0)
Tu-W16:3 Normal endothelial function in carriers of the apolipoprotein A-imilano mutant despite low HDL-cholesterol levels (2006) (0)
Abnormalities of Apolipoprotein B Metabolism in the Lipid Clinic (1991) (0)
Human Apolipoprotein Mutants III (1993) (0)
Association among cardiovascular risk factors and carotid atherosclerosis. A study in patients attending a lipid clinic in Italy (1998) (0)
Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials (2018) (0)
Th-P16:347 Rosuvastatin lacks transcriptional effects on ApoA-I in a transgenic mouse model (2006) (0)
Structure-function relationship in recombinant A-IM/A-IM (1995) (0)
Correction to: Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study (2019) (0)
VEGETABLE PROTRINS AS DRUGS (2004) (0)
1.W07.4 Evaluation of the clinical efficacy and potential mechanism of the cholesterol lowering effect of soy protein (1997) (0)
50 SMOKING HABITS AS DETERMINANT OF CAROTID IMT IN PATIENTS IN PRIMARY AND SECONDARY PREVENTION (2006) (0)
Gene-expression profiling of lymph nodes reveals that apoa-i deficiency in apoe-ko mice induces a dramatic activation of the immune response (2014) (0)
Gender-specific comparison of six QT correction formulae in dyslipidemic patients in primary prevention (2013) (0)
Effects of fenofibrate on the HDL system in hypoalphalipoproteinemia (2000) (0)
Soy proteins and LDL-receptors in HEPG2 cells (1997) (0)
Light or heavy cigarettes consumption and carotid atherosclerosis (2007) (0)
Carotid artery IMT measured with an electronic caliper in patients attending a lipid clinic (1997) (0)
2.P.175 Carotid atherosclerosis and vascular risk factors in patients attending an Italian Lipid Clinic (1997) (0)
Th-W55:6 Lupin proteins reduce progression of a focal atheromatous lesion in rabbits (2006) (0)
Author Correction: Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials (2020) (0)
Combined use of carotid IMT and traditional risk factors in predicting cardiovascular events in intermediate risk individuals (2004) (0)
4 CHRONIC USE OF LIGHT OR REGULAR CIGARETTES AND FLOW MEDIATED DILATION (2008) (0)
Light or regular cigarette smoking: effect on brachial artery flow mediated dilation (2012) (0)
Kinetics of insulin secretion following glucose infusion in patients with atherosclerotic peripheral vascular disease (1979) (0)
Process for the preparation of novel pyrimidine or s-triazine derivatives (1982) (0)
Comparison among sulfanilamide concentrations in the fetal, umbilical, maternal blood and amniotic fluid. (1971) (0)
Abstract: P901 LIGHT OR REGULAR CIGARETTES CONSUMPTION: EFFECT ON ENDOTHELIAL FUNCTION (2009) (0)
Human apolipoprotein mutants : impact on atherosclerosis and longevity (1986) (0)
Effects of metformin on plasma lipo proteins and apo lipo proteins in rabbits and man (1978) (0)
Kinetics of Exogenous Di-Linoleyl Phosphatidylcholine and Incorporation in Plasma and RBC Lipids in Man (1993) (0)
CAROTID INTIMA-MEDIA THICKNESS (C-IMT) : BIOMARKER, SURROGATE END POINT OR BOTH? (2003) (0)
Lowering of circulating lipids: Emerging problems (1990) (0)
Apolipoprotein AI-Milano: Mechanisms for the Antiatherogenic Potential (1989) (0)
MS63 PARADOXICAL DECREASE IN HIGH DENSITY LIPOPROTEIN CHOLESTEROL WITH FENOFIBRATE: A QUITE RARE PHENOMENON INDEED (2010) (0)
Abstract: S3-26 HDL FROM CARRIERS OF THE R37X MUTATION IN CETP GENE AND ENDOTHELIAL CELL HOMEOSTASIS (2009) (0)
Pravastatin inhibition of carotid intima-media thickness progression is not related to the extent of cholesterol reduction. The CAIUS Study (1998) (0)
Response to treatment and occurrence of cardiovascular (cv) complications in patients with autosomal recessive hypercholesterolemia (arh): A retrospective analysis (2016) (0)
Abstract: 120 STRUCTURAL AND FUNCTIONAL FEATURES OF HDL FROM CARRIERS OF THE R37X MUTATION IN CETP GENE (2009) (0)
ApoA-1 milano and regression of atherosclerosis. Author's reply (2004) (0)
Measurement of carotid artery intima-media thickness improves the power of traditional risk factors to predict cardiovascular events (2007) (0)
ApoA-1 Milano and Regression of Atherosclerosis [1] (multiple letters) (2004) (0)
Apolipoprotein A-II modulates HDL remodeling in human plasma (1994) (0)
Abstract: P913 MR IMAGING OF ATHEROSCLEROTIC PLAQUES IN BRACHIOCEPHALIC ARTERIES OF APOEKO MICE (2009) (0)
C26 A rabbit model of atherosclerosis which mimics human soft, lipid-rich, plaques (1999) (0)
Oral administration of polyunsaturated phosphatidylcholine reduces lipid and cholesterol contents in platelets of healthy volunteers. (1984) (0)
Tu-P9:337 Relationship between cardiovascular global risk in primary and secondary prevention and carotid atherosclerosis (2006) (0)
W06.166 Synthetic high density lipoproteins protect the heart against ischemia-reperfusion injury (2004) (0)
Triglycerided as predictor of tissue plasminogen activator and of tissue plasminogen activator inhibitor type 1 levels in non obese normo and hypertriglyceridemic subjects (1997) (0)
Inhibition of TNF-α induced VCAM-1 expression on human endothelial cells by reconstituted HDL (1997) (0)
Effect of Tetranectin-ApoA-I infusion on atherosclerosis and HDL-mediated cholesterol efflux capacity in hypercholesterolemic rabbits (2015) (0)
Effect of omega-3 PUFA on carotid IMT and hemostasis in hypertriglyceridemic patients: a longitudinal pilot study in primary prevention (2006) (0)
56 A NOVEL HOMOZYGOUS MUTATION IN CETP GENE AS A CAUSE OF CETP DEFICIENCY IN A CAUCASIAN KINDRED (2008) (0)
Tu-W16:8 A structural model for apolipoprotein A-I Milano (A-IM) in its heterodimeric form with apolipoprotein A-II (A-II) (2006) (0)
Male patients with hypogonadism have an impaired lipoprotein function (2019) (0)
Effects of unsaturated fatty acids on high density lipoprotein metabolism. (1994) (0)
Effect of coenzyme a infusions on postprandial triglyceride metabolism and PAI-1 levels in patients with moderate hypertriglyceridemia (1992) (0)
Hypertriglyceridemia and Atherosclerosis (1992) (0)
Eicosapentaenoic acid for prevention of major coronary events (2007) (0)
Lipoprotein Deficiency Syndromes (1989) (0)
Statin Myalgia is Detected by a Single Lipid Marker (2012) (0)
Subject Index Vol. 50, 2006 (2007) (0)
SAT-LB92 Sex Hormones Therapy Differentially Modulates HDL Function in Transgender Individuals (2020) (0)
CA-IMT and QT parameters in dyslipidemic patients in primary prevention at different ESC/EAS cardiovascular risk levels (2013) (0)
1198 – STUDIES ON THE MECHANISM OF THE ANTI-ATHEROSCLEROTIC EFFECT OF METFORMIN (1978) (0)
Erratum: Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients (Journal of Clinical Lipidology (2010) 4 (272-278) DOI: 10.1016/j.jacl.2010.05.002) (2011) (0)
Esterification, lipoprotein binding and excretion of the 14beta-stereoisomer of cholesterol. (1978) (0)
[Automatic spectrophotometrical method for simultaneous analysis of cholesterol and triglycerides in the plasma]. (1972) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Cesare Riccardo Sirtori?

Cesare Riccardo Sirtori is affiliated with the following schools: